You've chosen Americas as your location.

To clear your location selection and return to IPS Global, click below.

Return to IPS Global

You've chosen Americas as your location.

Thank you for choosing a location. This will help us show you the information that matters the most to you.

Continue Change Selection

IPS Successfully Delivers a Fast-Paced Project Amid COVID-19

Nov 19, 2020

IPS Delivers fast-paced project to WuXi Biologics amid COVID19 Precautions

IPS Successfully Delivers a Fast-Paced Project Amid COVID-19

Nov 19, 2020

Blue Bell, Pennsylvania, November 19, 2020 – IPS-Integrated Project Services, LLC, a leading provider of engineering, procurement, construction management, and validation (EPCMV) services, announces the successful delivery of the new process development and testing facility for WuXi Biologics, a leading global open-access biologics technology platform offering end-to-end solutions from concept to commercial manufacturing. WuXi Biologics partnered with IPS to renovate the 33,000 square-foot facility located in King of Prussia, PA, part of the emerging life sciences and biotech hub of the Greater Philadelphia region.

The site is the first of three WuXi Biologics facilities in the United States that will open in response to growing customer needs.

IPS executed the project in an extremely tight timeline and overcame the unusual challenges posed by COVID-19 restrictions, including severe limitations and interruptions to construction activities. In spite of those challenges, the IPS EPCMV team managed the site and delivered the project while complying with all safety measures, including IPS COVID-related policies, as well as those imposed by CDC and OSHA.

Even with the disruptions created by the COVID-19 pandemic, IPS’ integrated team of EPCMV professionals expedited project activities and completed the renovations and equipment installations in 7 months. The team met the project deadline, allowing WuXi Biologics to strengthen its ability to support biotech and biopharma partners.

“I couldn’t be prouder of our team for their relentless commitment to successfully deliver this important project for our client, WuXi Biologics,” stated Dave Goswami, IPS Chairman and CEO. “The project is a great example of our unique brand of integrated EPCMV delivery model and our collaboration with the project delivery supply chain. I want to congratulate Wuxi Biologics on the opening of this new facility that will ultimately benefit patients worldwide.”

WuXi Biologics announced the opening of its new process development and testing lab facility on October 8, 2020.

Download this full announcement here.

Related Happenings At IPS

Share this News Article


Choose Your Location

To customize your experience, select an IPS region or country to view specific information based on your location.

  • Americas
  • United States
  • Canada
  • Brazil
  • All Other Countries

You’ve chosen as your location.

Thank you for choosing a location. This will help us show the information that means to most to you. Continue to the homepage to view featured projects, and happenings specific to your location.


We use cookies to personalize and enhance your experience on our site. Visit our Privacy Policy to learn more.